Lovask-A 5 mg + 50 mg (Amlodipine + Atenolol) Tablets

Introduction:

Lovask-A 5 mg + 50 mg, manufactured by Beacon Pharmaceuticals Ltd and supplied by Orio Pharma, is a combination medication designed to provide effective management of hypertension (high blood pressure) and angina pectoris (chest pain). This dual-action therapy combines Amlodipine, a calcium channel blocker, with Atenolol, a beta-blocker, to deliver comprehensive cardiovascular protection. Lovask-A 5 mg + 50 mg is particularly beneficial for patients who require multiple medications to control their blood pressure and reduce the risk of cardiovascular events.

Manufacturing Excellence of Beacon Pharmaceuticals Ltd.:

Beacon Pharmaceuticals Ltd. is committed to producing high-quality pharmaceutical products that adhere to stringent international standards. The development of Lovask-A 5 mg + 50 mg reflects Beacon’s dedication to advancing cardiovascular treatments through innovative research, rigorous quality control, and adherence to best manufacturing practices. Their focus on safety and efficacy ensures that Lovask-A 5 mg + 50 mg is a reliable and effective option for patients managing hypertension and angina.

Mechanism of Action:

Lovask-A 5 mg + 50 mg combines two potent cardiovascular agents:

• Amlodipine (5 mg): Amlodipine is a calcium channel blocker that works by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle cells. This action leads to the relaxation of blood vessels, reducing vascular resistance, and lowering blood pressure. Amlodipine also helps to relieve angina by improving blood flow to the heart muscle, reducing the heart’s workload, and preventing chest pain.
• Atenolol (50 mg): Atenolol is a selective beta-blocker that reduces heart rate, myocardial contractility, and cardiac output by blocking the effects of adrenaline on the heart. This action helps to lower blood pressure and reduce the oxygen demand of the heart, making it an effective treatment for angina and hypertension.

The combination of Amlodipine and Atenolol in Lovask-A provides a synergistic effect, effectively managing blood pressure and angina through complementary mechanisms of action.

Clinical Applications:

Lovask-A 5 mg + 50 mg is indicated for the treatment of:

• Hypertension: Lovask-A is used to lower high blood pressure, reducing the risk of heart attacks, strokes, and other cardiovascular complications.
• Angina Pectoris: Lovask-A 5 mg + 50 mg is also indicated for the prevention of angina, providing relief from chest pain and improving exercise tolerance in patients with coronary artery disease.

Clinical studies have shown that the combination of Amlodipine and Atenolol is more effective in reducing blood pressure and preventing angina than either drug alone, offering a comprehensive approach to cardiovascular care.

Dosage and Administration:

The recommended dosage of Lovask-A 5 mg + 50 mg is one tablet taken once daily, preferably at the same time each day. The tablet should be swallowed whole with water, with or without food. It is crucial for patients to follow their healthcare provider’s instructions closely and to take the medication consistently to achieve the best possible outcomes. Regular monitoring of blood pressure, heart rate, and overall cardiovascular health is essential to assess the response to therapy and make any necessary dosage adjustments.

Benefits of Lovask-A 5 mg + 50 mg:

• Comprehensive Cardiovascular Protection: Lovask-A 5 mg + 50 mg offers dual-action therapy, effectively lowering blood pressure and reducing the risk of angina through the combined effects of Amlodipine and Atenolol.
• Improved Patient Compliance: The combination of two medications in a single tablet simplifies treatment regimens, improving patient adherence and ensuring consistent cardiovascular protection.
• Proven Efficacy: Clinical studies have demonstrated that the combination of Amlodipine and Atenolol is highly effective in managing hypertension and angina, reducing the risk of serious cardiovascular events.
• Convenient Dosing: The once-daily dosing of Lovask-A 5 mg + 50 mg allows for easy integration into daily routines, enhancing patient compliance and treatment outcomes.

Supplier: Orio Pharma

Orio Pharma ensures that Lovask-A 5 mg + 50 mg is readily available to healthcare providers and patients, offering reliable access to this essential cardiovascular therapy. Their commitment to efficient supply and distribution supports effective management of hypertension and angina, helping to improve patient outcomes.

Conclusion:

Lovask-A 5 mg + 50 mg (Amlodipine + Atenolol) by Beacon Pharmaceuticals Ltd, supplied by Orio Pharma, represents an advanced solution for the treatment of hypertension and angina. This dual-action therapy combines the benefits of a calcium channel blocker and a beta-blocker, offering comprehensive cardiovascular protection in a single tablet. By incorporating Lovask-A into their treatment plans, healthcare providers can offer patients a reliable and effective strategy for managing high blood pressure and reducing the risk of angina, ultimately leading to better health outcomes and improved quality of life.